{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019739","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.711183+00:00","generated_at":"2026-06-01T23:21:36.235204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivos Q1 revenue down 10.5% to $3.4M, operating expenses cut 22%; Medicare reimbursement approved for CARE devices","bullets":["Q1 revenue $3.4M vs $3.8M YoY; gross margin 57% vs 61%.","Operating expenses down 22% YoY ($1.6M reduction); operating loss reduced 24% YoY.","Cash $2.6M at March 31; Feb 2024 warrant exercise raised ~$4.0M from 980,393 shares.","April 2024: received Medicare reimbursement approval for CARE oral devices, enabling coverage for beneficiaries.","Management targets cash flow positive from operations by end of 2024 or Q1 2025, assuming revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019739","json":"https://secwatch.observer/filing/0001493152-24-019739.json","markdown":"https://secwatch.observer/filing/0001493152-24-019739.md","text":"https://secwatch.observer/filing/0001493152-24-019739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/0001493152-24-019739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:21:36.235204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f82dca200cc98d7ba0d86aae05a71edf3bbe004","claim":"Vivos Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.4 million.","evidence_excerpt":"Revenue was $3.4 million for the first quarter of 2024, compared to $3.8 million for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/0001493152-24-019739-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}